toripalimab
dinutuximab
sintilimab
pidilizumab
vanucizumab
abagovomab
immunoglobulin E
retifanlimab
antipolyvalent
atezolizumab
antigenically
antinucleosome
heterophile
agonistic monoclonal antibody
polyvalent
antisynthetase
heterophilic
heteroclitic
multiantigenic
polytypic
guselkumab
brentuximab
immunoglobin
elotuzumab
cytotoxic reaction
paratope
allotope
immunosorbent
sonepcizumab
tucotuzumab
polyantibody
cross-reactivity
alacizumab
oportuzumab monatox
immunoprobe
bivatuzumab
immunospecific
amlitelimab
crossreactive
antimonoclonal
anti-nuclear factor
intetumumab
microlymphocytotoxicity
polyantigenic
immunorepressive